Aim: The aim of this study was to analyze the hematological features in children with systemic lupus erythematosus (SLE) and to review our current treatment protocols. Methods: We evaluated hematological findings of 43 children with SLE diagnosed and followed at the Pediatric Rheumatology Division of Hacettepe University, Turkey. Thirty-seven patients with hematological abnormalities were analyzed in detail. Results: Median age at presentation was 13 years. Hematological involvement was seen in 86% of patients. The most common hematological finding was anemia (n = 30). Anemia was either a Coombs (+) hemolytic one, or was due to other causes. Hemolytic anemia was treated with steroids and intravenous gamma globulin (IVIG). Leucopenia and thrombocytopenia were detected in 35.1 % and 37.8 %, respectively. Bone marrow aspiration was performed in 15, mainly for cytopenia. Secondary dysplastic changes were common. Acute lymphoblastic leukemia (ALL) was diagnosed in one patient. Six patients were diagnosed as having macrophage activation syndrome (MAS). One patient died due to secondary infections and multiorgan failure despite aggressive treatment. In patients diagnosed early, treatment with steroids and cyclosporine resulted in an excellent response. Thrombotic microangiopathy was detected in two patients. Both were treated successfully with steroids and plasma exchange. Antiphospholipid and anticardiolipin antibodies were positive in 12 and 15 of the patients, respectively. Five developed deep vein thrombosis (DVT), one cerebral sinus thrombosis and one presented with purpura fulminans. They were effectively treated with anticoagulation protocol. Conclusion: Hematological findings should be carefully assessed and treated vigorously to prevent the morbidity and possible mortality.
AbdwaniRRizviSGEl-NourI. Childhood systemic lupus erythematosus in Sultanate of Oman: demographics and clinical analysis. Lupus2008; 17: 683–686.
2.
HuangJLYehKWYaoTC. Pediatric Lupus in Asia. Lupus2010; 19: 1414–1418.
3.
HochbergMC. for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Letter. Arthritis Rheum1997; 40: 1725–1725.
PuiCHRellingMVSandlundJF. Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia. Ann Hematol2004; 83: 124–126.
6.
ChalmersEGanesenVLiesnerR. Guideline on the investigation, management and prevention of venous thrombosis in children. Br J Hematol2011; 154: 196–207.
7.
EichingerSMinarEBialonczykC. D-dimer levels and risk of recurrent venous thromboembolism. JAMA2003; 290: 1071–1074.
8.
DemirkayaECakmakliHFGüçerS. Purpura fulminans as the presenting manifestation in a patient with juvenile SLE. Turk J Pediatr2009; 51: 378–380.
9.
MuzafferMAAl-MayoufSM. Clinical and laboratory variables of childhood systemic lupus erythematosus in western province of Saudi Arabia. Rheumatol Int2011; 31: 23–26.
10.
SolskyMAWallaceDJ. New therapies in systemic lupus erythematosus. Review. Best Pract Res Clin Rheumatol2002; 16: 293–312.
RönnblomL. Potential role of IFNα in adult lupus. Arthritis Res Ther2010; 12(Suppl. 1): S3–S3.
19.
VasiliuIMPetriMABaerAN. Therapy with granulocyte colony-stimulating factor in systemic lupus erythematosus may be associated with severe flares. J Rheumatol2006; 33: 1878–1880.
20.
MokCCLeeKWHoCT. A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population. Rheumatology2000; 39: 399–406.
ParodiADaviSPringeAB. Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. Arthritis Rheum2009; 60: 3388–3399.
23.
SawhneySWooPMurrayKJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child2001; 85: 421–426.
24.
FukayaSYasudaSHashimotoT. Clinical features of haemophagocytic syndrome in patients with systemic autoimmune diseases: analysis of 30 cases. Rheumatology2008; 47: 1686–1691.
25.
MatsumotoYNaniwaDBannoS. The efficacy of therapeutic plasmapheresis for the treatment of fatal hemophagocytic syndrome: two case reports. Ther Apher1998; 2: 300–304.
EsmonNLSmirnovMDEsmonCT. Lupus anticoagulant and thrombosis: the role of phospholipids. Review. Haematologica1997; 82: 474–477.
28.
AvcinTCimazRSilvermanED. Pediatric antiphospholipid syndrome: clinical and immunological features of 121 patients in an international registry. Pediatrics2008; 122: 1100–1107.
29.
SchulmanSSvenungssonEGranqvistS. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med1998; 104: 332–338.
30.
MuscalEEdwardsRMKearneyDL. Thrombotic microangiopathic hemolytic anemia with reduction of ADAMST13 activity: initial manifestation of childhood-onset systemic lupus erythematosus. Am J Clin Pathol2011; 135: 406–416.
31.
Polido-PereiraJFerreiraDRodriquesAM. Rituximab use in pediatric autoimmune diseases: four case reports. Ann N Y Acad Sci2009; 1173: 712–720.
32.
SultanSMIoannouYIsenbergDA. Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long-term review. Rheumatology2000; 39: 1147–1152.
33.
BjömadalLLöfströmBYinL. Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol2002; 31: 66–71.
34.
LöfströmBBacklinCSundströmC. Myeloid leukemia in systemic lupus erythematosus — a nested case-control study based on Swedish registers. Rheumatol2009; 48: 1222–1226.
35.
BoumpasDTTsokosGCMannDL. Increased proto-oncogene expression in peripheral blood lypmhocytes from patients with systemic lupus eythematosus and other autoimmune diseases. Arthritis Rheum1986; 29: 755–760.
36.
LeoneGPaganoLBen-YehudaD. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Hematologica2007; 92: 1389–1398.
